In this Review:
New genetic mutations linked to ovarian cancer risk
Avelumab shows anticancer activity in heavily pretreated patients
Hormonal maintenance therapy in low-grade serous carcinoma
Olaparib: OS advantage in platinum-sensitive serous ovarian cancer
IP carboplatin + dose-dense paclitaxel in suboptimal residual disease
MMS vs USS or no screening in UKCTOCS
Prolonged platinum-free interval: no survival benefit
Topotecan ± sorafenib in platinum-resistant disease
A multi-marker panel for early detection of ovarian cancer?
Prognostic value of TILs & PDL1 expression after neoadjuvant therapy
Please login below to download this issue (PDF)